Mark Jurgens
About Mark Jurgens
Mark Jurgens serves as the Executive Director and Head of External Scientific Collaboration in Medical Affairs at Kite Pharma. He has held various leadership roles in prominent pharmaceutical companies, including Merck, Bristol-Myers Squibb, and Roche, and possesses advanced degrees in Biotechnology and Business Administration.
Work at Kite Pharma
Mark Jurgens serves as the Executive Director and Head of External Scientific Collaboration in Medical Affairs at Kite Pharma. He has held this position since 2020, contributing to the company's focus on innovative cancer therapies. His role involves fostering collaborations with external scientific entities to enhance research and development efforts. Kite Pharma is known for its commitment to advancing cell therapy and improving patient outcomes.
Previous Experience at Merck
Before joining Kite Pharma, Mark Jurgens worked at Merck as the Executive Director of Global Program & Alliance Management. His tenure lasted for one year, from 2018 to 2019, based in Rahway, New Jersey. In this role, he was responsible for overseeing global programs and managing strategic alliances, contributing to the company’s objectives in pharmaceutical development.
Experience at Bristol-Myers Squibb
Mark Jurgens held the position of Director, R&D Transformation, Strategy, and Planning Lead at Bristol-Myers Squibb from 2017 to 2018. His work was based in Princeton, New Jersey, where he focused on transforming research and development strategies to align with the company’s goals in the biopharmaceutical sector.
Background in Roche
Mark Jurgens has extensive experience at Roche, where he held multiple roles. He was the Global Head of Operations for pRED R&D Collaborations & Alliances from 2015 to 2017 in New York, NY. Prior to that, he served as the Head of the Singapore Translational Medicine Hub from 2010 to 2015 and as Global Alliances Director from 2006 to 2010 in London, United Kingdom. His roles at Roche involved managing collaborations and operational strategies in research and development.
Education and Expertise
Mark Jurgens holds a Master's degree in Biotechnology from the University of Leeds. Additionally, he earned a Master of Business Administration from the University of Warwick - Warwick Business School, completing his studies from 2000 to 2004. His educational background supports his expertise in both scientific and business aspects of the pharmaceutical industry.